Related Experiment Video

Updated: Aug 24, 2025

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

297

Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders

Heena Khan1, Chanchal Tiwari1, Amarjot Kaur Grewal1

  • 1Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.

Inflammopharmacology
|October 22, 2022
PubMed

Insights

Phosphodiesterase 7 (PDE7) inhibitors show promise for treating neurodegenerative diseases by normalizing cyclic nucleotide signaling. Research explores PDE7

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Neurodegenerative diseases stem from genetic defects impacting biological processes and genomic products.
  • These conditions involve the degradation of cyclic nucleotides, including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
  • Phosphodiesterase 7 (PDE7) plays a crucial role in modulating intracellular cAMP signaling, vital for physiological and pathological functions.

Purpose of the Study:

  • To investigate the role of phosphodiesterases (PDEs), specifically PDE7, in the pathogenesis of neurodegenerative diseases.
  • To explore PDE7 inhibition as a potential therapeutic strategy for neurodegenerative disorders.
  • To review the impact of PDE7 alterations in conditions such as Alzheimer's, Parkinson's, and multiple sclerosis.

Main Methods:

  • Review of existing literature on PDE7 expression and function in neurodegenerative conditions.
  • Analysis of studies utilizing PDE7 inhibitors in animal models of neurological diseases.
  • Examination of signaling pathways, including cAMP/CREB/GSK/PKA, modulated by PDE7.

Main Results:

  • Alterations in PDE7 expression are linked to several neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis, Huntington's disease, Parkinson's disease, stroke, and epilepsy.
  • PDE7 inhibitors (e.g., VP3.15, VP1.14) have demonstrated positive outcomes in animal models of Alzheimer's, Parkinson's, and multiple sclerosis.
  • Modulation of cAMP/CREB/GSK/PKA pathways involving PDE7 is a key aspect of neurodegenerative disease mechanisms.

Conclusions:

  • Normalizing cyclic nucleotide signaling via PDE inhibition presents a promising therapeutic avenue for neurodegenerative diseases.
  • PDE7 and its subtypes are significant targets for future research into the etiology and treatment of these debilitating conditions.
  • Further investigation into PDE7-mediated pathways could unlock novel treatment strategies for a range of neurological disorders.
Keywords:
Cyclic adenosine monophosphateNeurodegenerative diseasePDE-7PhosphodiesterasescGMP

More Related Videos

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons10:50

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons

Published on: April 24, 2021

1.1K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

3.8K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
247
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
353
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
671
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
751
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
189
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K